Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 2/20 | 0.56 |
| ▸ | MC3R | P41968 | 2/20 | 0.56 |
| ▸ | MC1R | Q01726 | 2/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serdemetan SCHEMBL29375950 | 0.86 | HRH3 (0.58) | MC5RMC3RMC1RHTR2AALDH1A1 | |
| Serdemetan SCHEMBL3012498 | 0.86 | HRH3 (0.58) | MC5RMC3RMC1RHTR2AALDH1A1 | |
| SCHEMBL12782485 | 0.85 | HDAC3 (0.56) | MC5RMC3RMC1RHTR1AHRH3 | |
| SCHEMBL2086151 | 0.83 | KMT2A (0.60) | MC5RMC3RMC1RG6PDHTR2A | |
| SCHEMBL12782504 | 0.82 | MC1R (0.52) | MC5RMC3RMC1RALDH1A1KDM4E | |
| SCHEMBL12782483 | 0.81 | HDAC3 (0.56) | MC5RMC3RMC1RHTR2AALDH1A1 | |
| SCHEMBL6165432 | 0.81 | MC5R (0.71) | MC5RMC3RMC1RG6PDHTR2A | |
| SCHEMBL12782284 | 0.81 | HRH3 (0.61) | MC5RMC3RMC1RHTR2AALDH1A1 | |
| SCHEMBL12845524 | 0.81 | HDAC3 (0.53) | MC5RMC3RMC1RHTR2AALDH1A1 | |
| SCHEMBL17232881 | 0.80 | MC5R (0.83) | MC5RMC3RMC1RG6PDHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | MC5R 3658/4885MC3R 3348/4885MC1R 2348/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | MC5R 3658/4885MC3R 3348/4885MC1R 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.